The Technical Analyst
Ekso Bionics Holdings Inc [EKSO]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Instruments & Supplies
Ekso Bionics Holdings Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.54% $1.210
America/New_York / 25 apr 2024 @ 11:26
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 21.66 mill |
| EPS: | -1.100 |
| P/E: | -1.100 |
| Earnings Date: | Apr 25, 2024 |
| SharesOutstanding: | 17.90 mill |
| Avg Daily Volume: | 0.167 mill |
| RATING 2024-04-24 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.100 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -1.100 | industry: PE 33.06 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.082 - 1.338 ( +/- 10.58%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-22 | Wong Jerome | Buy | 7 474 | Common Stock |
| 2024-03-22 | Jones Jason C | Buy | 7 474 | Common Stock |
| 2023-06-12 | Jones Jason C | Buy | 10 800 | Common Stock |
| 2022-02-17 | Jones Jason C | Buy | 3 446 | Common Stock |
| 2023-11-02 | Lathan Corinna | Buy | 4 032 | Common Stock |
| INSIDER POWER |
|---|
| 78.84 |
| Last 97 transactions |
| Buy: 2 939 949 | Sell: 372 739 |
Forecast:
13:05 - $1.203
Live Trading Signals (every 1 min)
Forecast
1: 11:35 - $1.241
Forecast 2: 12:25 - $1.223
Forecast 3: 13:05 - $1.203
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.210 (2.54% ) |
| Volume | 0.0527 mill |
| Avg. Vol. | 0.167 mill |
| % of Avg. Vol | 31.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EKSO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EKSO
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.
Latest Press Releases
2024-04-22 08:00:00 - Press Release
Ekso Bionics To Report First Quarter 2024 Financial Results On April 29, 2024
San rafael, calif., april 22, 2024 (globe newswire) -- ekso bionics holdings, inc. (nasdaq: ekso) (the “company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2024 after the close of trading on monday, april 29, 2024. management will host a conference call beginning at 1:30 p.m. pt / 4:30 p.m. et to discuss the financial results and recent business developments.
2024-04-12 08:00:00 - Press Release
Ekso Bionics Receives Final Payment Determination For Medicare Reimbursement From The Centers For Medicare & Medicaid Services (cms) For Ekso Indego Personal
San rafael, calif., april 12, 2024 (globe newswire) -- ekso bionics holdings, inc. (nasdaq: ekso) (the “company” or “ekso bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that the pricing, data analysis, and coding (“pdac”) contractor for the centers for medicare & medicaid services (“cms”) has determined a final payment level of $91,031.93 for medicare reimbursement of the ekso indego personal, which took effect on april 1, 2024.
2024-03-04 16:05:00 - Press Release
Ekso Bionics Reports Record Annual Revenue Of $18.3 Million
Sold record number of annual eksohealth units in 2023 san rafael, calif., march 04, 2024 (globe newswire) -- ekso bionics holdings, inc. (nasdaq: ekso) (the “company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended december 31, 2023.
2024-01-08 16:05:00 - Press Release
Ekso Bionics Launches Gaitcoach Software For Eksonr
San rafael, calif., jan. 08, 2024 (globe newswire) -- ekso bionics holdings, inc. (nasdaq: ekso) (the “company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the launch of gaitcoach™, its next generation gait therapy software for eksonr.
2024-01-04 17:05:00 - Press Release
Ekso Bionics Reports Certain Preliminary Fourth Quarter And Full Year 2023 Financial Results
San rafael, calif., jan. 04, 2024 (globe newswire) -- ekso bionics holdings, inc. (nasdaq: ekso) (the “company”), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended december 31, 2023.
Latest News
2024-04-22 08:00:00 - GlobeNewsWire
Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024
SAN RAFAEL, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2024 after the close of trading on Monday, April 29, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.
2024-03-04 20:07:17 - Seeking Alpha
Ekso Bionics Holdings, Inc. (EKSO) Q4 2023 Earnings Call Transcript
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q4 2023 Earnings Conference Call March 4, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Scott Davis - Chief Executive Officer Jerome Wong - Chief Financial Officer Jason Jones - Chief Operating Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Ben Haynor - Alliance Global Partners Operator Greetings, and welcome to the Ekso Bionics' Fourth Quarter 2023 Financial Results Conference Call.
2024-03-04 18:21:06 - Zacks Investment Research
Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue Estimates
Ekso Bionics (EKSO) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.24 per share a year ago.
2024-02-06 10:56:09 - Zacks Investment Research
Here's Why Ekso Bionics (EKSO) Is a Great 'Buy the Bottom' Stock Now
Ekso Bionics (EKSO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
2024-01-31 07:05:15 - Zacks Investment Research
New Strong Buy Stocks for January 31st
ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
2024-01-26 08:20:16 - InvestorPlace
Why Is Ekso Bionics (EKSO) Stock Up 5% Today?
Ekso Bionics (NASDAQ: EKSO ) stock is on the rise Friday without any clear news from the exoskeleton company this morning. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today.
2023-10-26 18:48:55 - Zacks Investment Research
Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates
Ekso Bionics (EKSO) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.33 per share a year ago.
2023-10-19 16:05:00 - GlobeNewsWire
Ekso Bionics to Report Third Quarter 2023 Financial Results on October 26, 2023
SAN RAFAEL, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2023 after the close of trading on Thursday, October 26, 2023. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.
2023-09-11 08:00:00 - GlobeNewsWire
Ekso Bionics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
SAN RAFAEL, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, Chief Executive Officer, and Jerome Wong, Chief Financial Officer, will be participating in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference taking place in New York on September 11-13, 2023.
2023-07-27 18:28:24 - Zacks Investment Research
Ekso Bionics (EKSO) Reports Q2 Loss, Tops Revenue Estimates
Ekso Bionics (EKSO) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.23 per share a year ago.